Vaccines · 2025
Heterologous DNA-Adenovirus Prime-Boost Strategy Expressing Bluetongue Virus VP2 and VP7 Proteins Protects Against Virulent Challenge.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nogales-Altozano Pablo, Gómez-Marcos Laro, Carlón Ana Belén, Louloudes-Lázaro Andrés, Rivera-Rodríguez Alicia, Larraga Jaime, Alcolea Pedro J, Alonso Ana, Larraga Vicente, Martín Verónica, Rojas José M, Sevilla Noemí
Аннотация
BACKGROUND/OBJECTIVES: Bluetongue virus (BTV) is an emerging arbovirus causing significant economic losses in the ruminant industry. Current vaccines offer limited cross-protection against heterologous serotypes and do not enable differentiation between infected and vaccinated animals (DIVA). Subunit-based vaccines provide a potential DIVA-compatible solution. This study aimed to develop a vaccination protocol expressing BTV structural proteins VP7 or VP2 using antibiotic-resistance-free DNA plasmids and replication-defective adenovirus vectors.
METHODS: We evaluated homologous DNA prime-boost and heterologous DNA prime-adenovirus boost strategies in a murine model, assessing adaptive immune responses and protection against virulent BTV challenge.
RESULTS: The heterologous DNA-adenovirus prime-boost strategy expressing both antigens conferred full protection, preventing viremia, while homologous DNA-DNA prime-boost provided only partial protection. Both VP7 and VP2 elicited cellular and humoral immune responses, but the heterologous strategy significantly enhanced anti-BTV IgG, neutralizing antibody titers, and T cell activation. CD8+ T cell responses showed the strongest correlation with viral load reduction, suggesting that cellular immunity to conserved VP7 could serve as a platform for cross-protection against multiple BTV serotypes.
CONCLUSIONS: These findings highlight the potential of heterologous DNA-adenovirus vaccination as an effective DIVA-compatible strategy for BTV control. By inducing strong and protective immune responses, this approach could improve disease surveillance and management, ultimately reducing the impact of BTV on livestock industries.
METHODS: We evaluated homologous DNA prime-boost and heterologous DNA prime-adenovirus boost strategies in a murine model, assessing adaptive immune responses and protection against virulent BTV challenge.
RESULTS: The heterologous DNA-adenovirus prime-boost strategy expressing both antigens conferred full protection, preventing viremia, while homologous DNA-DNA prime-boost provided only partial protection. Both VP7 and VP2 elicited cellular and humoral immune responses, but the heterologous strategy significantly enhanced anti-BTV IgG, neutralizing antibody titers, and T cell activation. CD8+ T cell responses showed the strongest correlation with viral load reduction, suggesting that cellular immunity to conserved VP7 could serve as a platform for cross-protection against multiple BTV serotypes.
CONCLUSIONS: These findings highlight the potential of heterologous DNA-adenovirus vaccination as an effective DIVA-compatible strategy for BTV control. By inducing strong and protective immune responses, this approach could improve disease surveillance and management, ultimately reducing the impact of BTV on livestock industries.